Management of Patients with Medetomidine Withdrawal During Interfacility Transfer

The authors aimed to evaluate the management and outcomes of patients experiencing medetomidine withdrawal during interfacility transport while receiving dexmedetomidine infusion. Their study found that while many patients exhibited significant withdrawal symptoms, such as hypertension and tachycardia, most remained stable on dexmedetomidine without requiring additional sedative infusions or advanced airway management. The findings suggest that early recognition of symptoms and continued pharmacologic support are crucial for safe transport of these patients.